Emergent BioSolutions | EBS - Cost Of Sales


Emergent BioSolutions reported $381.2M in Cost of Sales for its fiscal quarter ending in June of 2023.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
ALKERMES USD 73.25M 27.04M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amarin USD 26.05M 1.41M Dec/2025
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Exelixis USD 19.95M 6.53M Mar/2026
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Merck USD 2.94B 380M Mar/2026
Moderna USD 955M 503M Mar/2026
Myriad Genetics USD 63M 1.1M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Pacira USD 50.74M 3.89M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Sanofi EUR 3.67B 621M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
United Therapeutics USD 133.4M 341.3M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Xoma 116K 112.7K Jun/2024